SCHEMBL26077041

SCHEMBL26077041

COCCn1cc(-c2ccccc2)c(C(F)(F)F)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPO P05164 4/20 0.43
KCNH2 Q12809 1/20 0.42
LIPC P11150 1/20 0.41
POLB P06746 1/20 0.40
LRRK2 Q5S007 2/20 0.40
IRAK4 Q9NWZ3 3/20 0.39
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
HPGD P15428 1/20 0.38
MAP4K4 O95819 1/20 0.38
EGFR P00533 1/20 0.38
FRK P42685 1/20 0.38
MAPK9 P45984 1/20 0.38
CSNK1D P48730 1/20 0.38
SLK Q9H2G2 1/20 0.38
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37
TSHR P16473 2/20 0.37
PTGIR P43119 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26076498 0.90 HPGD (0.40) MPOKCNH2LIPCPOLBLRRK2
SCHEMBL24961563 0.81 POLB (0.42) MPOKCNH2POLBALDH1A1HPGD
SCHEMBL15473395 0.76 LRRK2 (0.45) MPOKCNH2LIPCPOLBLRRK2
SCHEMBL7039667 0.76 POLB (0.49) POLBALDH1A1LMNACYP1A2KMT2A
SCHEMBL21819845 0.75 LRRK2 (0.44) MPOKCNH2LIPCPOLBLRRK2
SCHEMBL17076862 0.75 LRRK2 (0.44) MPOKCNH2LIPCPOLBLRRK2
SCHEMBL21408546 0.73 GAA (0.44) MPOLIPCPOLBLRRK2IRAK4
SCHEMBL26076489 0.73 PTGIR (0.40) MPOKCNH2POLBALDH1A1TSHR
SCHEMBL26452723 0.72 LRRK2 (0.42) MPOKCNH2LIPCLRRK2IRAK4
SCHEMBL26076491 0.71 MEN1 (0.38) MPOKCNH2POLBIRAK4MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303584-A1 4,5,6,7-TETRAHYDROTHIENO[2,3-C]PYRIDINE SUMO INHIBITORS AND USES THEREOF CIT THERAPEUTICS LLC 2023-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303584-A1 4,5,6,7-TETRAHYDROTHIENO[2,3-C]PYRIDINE SUMO INHIBITORS AND USES THEREOF SUMO1, SUMO3, SUMO2 MPO 3509/4885KCNH2 4602/4885LIPC 3207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.